| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,680,982 | -1,578,276 | -1,992,790 | -4,395,472 |
| Share-based compensation | 258,287 | 294,794 | 294,793 | 657,814 |
| Share-based payments to vendors | 61,000 | 81,000 | 45,059 | 196,260 |
| Other receivable | 7,896 | 8,209 | 0 | -10,919 |
| Prepaid expenses | 143,808 | -73,183 | 104,679 | -46,601 |
| Accounts payable and accrued expenses | 105,866 | -47,232 | -123,352 | -238,195 |
| Net cash used in operating activities | -1,407,533 | -1,184,740 | -1,880,969 | -3,722,073 |
| Reverse stock split fractional share adjustment | NaN | 0 | 1,040 | NaN |
| Proceeds from warrant inducement, net of issuance costs | NaN | 0 | 0 | 2,480,553 |
| Proceeds from 2025 march registered direct offering, net of issuance costs | NaN | 0 | 0 | 889,420 |
| Proceeds from 2025 january registered direct offering, net of issuance costs | NaN | 0 | 0 | 2,099,253 |
| Proceeds from warrant exercise | NaN | 1,360,544 | NaN | NaN |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | 3,106,246 | 1,473,494 | 1,724,683 | 610,262 |
| Net cash provided by financing activities | 3,106,246 | 2,834,038 | 1,723,643 | 6,079,488 |
| Net increase/(decrease) in cash | 1,698,713 | 1,649,298 | -157,326 | 2,357,415 |
| Cash at beginning of year | 7,556,100 | 5,906,802 | 3,706,713 | NaN |
| Cash at end of year | 9,254,813 | 7,556,100 | 5,906,802 | NaN |
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)